Oncotelic Therapeutics files NT 10-Q for Q3 2025, seeks extension

Oncotelic Therapeutics, Inc. filed a Form 12b-25, notifying a late Form 10-Q for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. filed a Form 12b-25, notifying a late Form 10-Q for the quarter ended September 30, 2025.

The company says it was unable to compile the necessary financial information to complete the filing without unreasonable effort or expense and expects to file within the permitted extension period. The notification lists Amit Shah, Chief Financial Officer, as the signatory and contact.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OTLC file and for which period?

Oncotelic Therapeutics filed a Form 12b-25 (NT 10-Q) for the quarter ended September 30, 2025.

Why did OTLC file an NT 10-Q?

The company was unable to compile necessary financial information to complete the 10-Q without unreasonable effort or expense.

When does OTLC expect to file the delayed 10-Q?

The company expects to file within the permitted extension period.

Who is the contact for the NT 10-Q filing at OTLC?

Amit Shah, Chief Financial Officer, is listed with telephone (650) 635-7000.

Did OTLC indicate significant changes in results for Q3 2025?

The form includes a question on significant changes; the excerpt does not show a response.

What is Form 12b-25 (NT 10-Q)?

It is a notice that a periodic report will be late and indicates the company’s plan to file within the SEC’s extension window.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 05:15 PM Learn about SEC filing dates

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

Commission File Number: 000-21990

Notification of Late Filing

(Check One):

☐ Form 10-K   ☐ Form 20-F    ☐ Form 11-K    ☒ Form 10-Q    ☐ Form N-SAR

For Period Ended: September 30, 2025

	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q
	☐	Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

Part I - Registrant Information

Oncotelic Therapeutics, Inc.

Full Name of Registrant

Mateon Therapeutics, Inc.

Former Name if Applicable

29397 Agoura Road Suite 107

Address of Principal Executive Office (Street and Number)

Agoura Hills, CA 91301

City, State and Zip Code

Part II - Rules 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-(b), the following should be completed. (Check box, if appropriate)

☒ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N- SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

☒ (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

Part III - Narrative

State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof could not be file within the prescribed period.

The Company is working on and unable to compile the necessary financial information required to prepare a complete filing. Thus, the Company would be unable to file the periodic report in a timely manner without unreasonable effort or expense. The Company expects to file within the extension period.

Part IV - Other Information

(1) Name and telephone number of person to contract in regard to this notification.

Amit Shah		(650)		635-7000
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Oncotelic Therapeutics, Inc.

(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 14, 2025	By:	/s/ Amit Shah
	Amit Shah
	Its:	Chief Financial Officer